Gastrointestinal Adenocarcinomas
Conditions
Keywords
MEDI-565, gastrointestinal adenocarcinomas, carcinoembryonic antigen, bispecific T-cell engager
Brief summary
To determine the maximum tolerated dose and/or optimum biologic dose of MEDI-565 in adult subjects and evaluate the safety profile in adult subjects with advanced gastrointestinal adenocarcinomas who have no available standard or curative treatments.
Detailed description
This is a FTIH, dose-escalation and expansion Phase 1 study. The first part is a multicenter, open-label, single-arm, dose-escalation study of MEDI-565 to determine the MTD or OBD and evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI 565 in adult subjects who have GI adenocarcinomas for which no standard or curative treatments are available. The second part is a dose-expansion study at the MTD or OBD in subjects with selected tumor types.
Interventions
DRUGMEDI-565
MEDI-565 will be administered by IV infusion
Sponsors
MedImmune LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years of age at the time of screening * Adequate contraception from screening through end of trial * For the dose-escalation phase, subjects with GI adenocarcinomas with no available standard or curative treatments * Adequate hematological function * Adequate organ function * For subjects who had prior treatment with chemotherapy, biological therapy, radiotherapy, or had prior surgery: eligible for study entry if at least 30 days have passed since their treatment/surgery * Life expectancy of at least 3 months * Karnofsky performance status ≥ 70% * Body weight ≥ 45 kg
Exclusion criteria
* Concurrent enrollment in another clinical study * Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals * Prior treatment with MEDI-565 * History of allergy or reaction to any component of the MEDI-565 formulation * History of malignancy other than GI adenocarcinoma, within 5 years prior to study entry, with the exception of ductal carcinoma in situ of the breast, basal cell carcinoma of the skin or carcinoma in situ of the cervix successfully treated with curative therapy * Diagnosis of hepatocellular carcinoma * Clinical history of significant CNS pathology * Active bacterial infection or known bacteremia. * Vaccination within 2 weeks prior to initiation of MEDI-565 * Infection with HIV-1 or HIV-2; chronic infection with hepatitis B or C * History of primary immunodeficiency * History of chronic autoimmune disease * Elective surgery planned during the study period through 30 days after discontinuation of MEDI-565. * Treatment with any chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment within 30 days prior to study entry and not recovered from treatment * Treatment with any investigational agent within 30 days prior to initiation of MEDI-565 * Regular dose of systemic corticosteroids during the 30 days prior to initiation of MEDI-565 or anticipated need of corticosteroids exceeding prednisone 40 mg/day of prednisone or equivalent during the trial, or any other systemic immunosuppressive therapy within 30 days prior to study entry (some maintenance doses allowed) * Contraindication to any protocol-specified concomitant medications administered during this study * Pregnancy or lactation * Evidence of any uncontrolled systemic disease (other than GI adenocarcinoma) * Recent history of cardiac disease, including myocardial infarction, unstable angina pectoris or uncontrolled arrhythmia within 6 months, or evidence of severe congestive heart failure * A marked baseline prolongation of corrected QT interval interval
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI-565 in subjects with gastrointestinal (GI) adenocarcinomas for which no standard or curative treatments are available. | MTD/OBD will be evaluated from the time of first administration of MEDI-565 through the first 28-day cycle | MTD/OBD will be determined based on Dose Limiting Toxicities that will be evaluated from the time of first administration of MEDI-565 through the first 28-day cycle |
| Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments. | AEs and SAEs will be reported through 30 days after the last dose of MEDI 565 | The number (percentage) of subjects with AEs and SAEs reported through 30 days after the last dose of MEDI 565 will be summarized for all subjects who received at least one dose of study drug (Safety Population). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the safety and antitumor activity of MEDI-565 in the dose-expansion phase. | 3 years | The antitumor activity of MED-565 will be assessed using objective response rate (ORR), time to response (TTR), duration of response (DR), time to progression (TTP), progression-free survival (PFS), and overall survival (OS) using RECIST guidelines |
| Pharmacokinetics of MEDI-565 | 3 years | Individual MEDI-565 concentrations will be tabulated by dose cohort along with descriptive statistics. Noncompartmental PK data analysis will be performed for data obtained from each dose cohort with scheduled PK sample collection. If the data allow, descriptive statistics of noncompartmental PK parameters (AUC, Cmax, Tmax, CL, Vd, t½) will be provided. |
| Immunogenicity of MED-565 | 3 years | The immunogenic potential of MEDI-565 will be assessed by summarizing the number and percentage of subjects who develop detectable anti-drug antibodies. |
Countries
United States
Outcome results
None listed